within Pharmacolibrary.Drugs.ATC.N;

model N05CD08_1
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.3,
    Cl             = 0.00039333333333333337,
    adminDuration  = 600,
    adminMass      = 15 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.040600000000000004,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0009333333333333333,
    Tlag           = 600,            
    Vdp             = 0.0722,
    k12             = 38.6,
    k21             = 38.6
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>N05CD08_1</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Midazolam is a short-acting benzodiazepine used for sedation, anesthesia, procedural sedation, or the treatment of acute seizures. It is approved for medical use and is commonly administered in hospitals for premedication before surgeries, sedation in intensive care, and acute seizure management.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetics described for healthy adult volunteers after a single oral dose.</p><h4>References</h4><ol><li><p>Nordt, SP, &amp; Clark, RF (1997). Midazolam: a review of therapeutic uses and toxicity. <i>The Journal of emergency medicine</i> 15(3) 357–365. DOI:<a href=\"https://doi.org/10.1016/s0736-4679(97)00022-x\">10.1016/s0736-4679(97)00022-x</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/9258787/\">https://pubmed.ncbi.nlm.nih.gov/9258787</a></p></li><li><p>Toyama, K, et al., &amp; Ishizuka, H (2021). Effects of Repeated Oral Administration of Esaxerenone on the Pharmacokinetics of Midazolam in Healthy Japanese Males. <i>European journal of drug metabolism and pharmacokinetics</i> 46(5) 685–694. DOI:<a href=\"https://doi.org/10.1007/s13318-021-00701-4\">10.1007/s13318-021-00701-4</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/34383278/\">https://pubmed.ncbi.nlm.nih.gov/34383278</a></p></li><li><p>Tuey, SM, et al., &amp; Joy, MS (2022). The Impact of Suboptimal 25-Hydroxyvitamin D Levels and Cholecalciferol Replacement on the Pharmacokinetics of Oral Midazolam in Control Subjects and Patients With Chronic Kidney Disease. <i>Journal of clinical pharmacology</i> 62(12) 1528–1538. DOI:<a href=\"https://doi.org/10.1002/jcph.2104\">10.1002/jcph.2104</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/35678297/\">https://pubmed.ncbi.nlm.nih.gov/35678297</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end N05CD08_1;
